Steward Partners Investment Advisory LLC boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 11.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 44,579 shares of the biopharmaceutical company’s stock after buying an additional 4,569 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Bristol-Myers Squibb were worth $2,731,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Atlantic Trust LLC purchased a new stake in shares of Bristol-Myers Squibb during the second quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC raised its stake in shares of Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the period. Blue Chip Partners Inc. raised its stake in shares of Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the period. Horan Capital Advisors LLC. purchased a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $122,000. Finally, BDO Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the second quarter valued at approximately $123,000. Hedge funds and other institutional investors own 69.82% of the company’s stock.
A number of brokerages recently issued reports on BMY. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research note on Wednesday, November 1st. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price target for the company. in a research note on Friday, December 22nd. Finally, Credit Suisse Group restated a “hold” rating and issued a $61.00 price target (up previously from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $66.73.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $68.96 on Tuesday. The company has a market cap of $112,582.92, a price-to-earnings ratio of 116.88, a price-to-earnings-growth ratio of 2.14 and a beta of 1.09. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 1-year low of $51.56 and a 1-year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 earnings per share. equities analysts forecast that Bristol-Myers Squibb Co will post 3.21 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.32%. The ex-dividend date of this dividend was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 271.19%.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/20/steward-partners-investment-advisory-llc-boosts-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.